Skip to content
10-Q

Quarterly Report

IGC Pharma, Inc. IGC

0001185185-24-001096

← back to feed
Filed
Nov 12, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Nov 7, 2024 77.45M sh
Long Term Debt Q2 2025 · Sep 30, 2024 $135K
Long Term Debt Q2 2025 · Mar 31, 2024 $137K
Short Term Debt Q2 2025 · Sep 30, 2024 $3K
Short Term Debt Q2 2025 · Mar 31, 2024 $3K
Cash And Equivalents Q2 2025 · Sep 30, 2024 $1.55M
Cash And Equivalents Q2 2025 · Mar 31, 2024 $1.2M
Current Liabilities Q2 2025 · Sep 30, 2024 $2.8M
Current Liabilities Q2 2025 · Mar 31, 2024 $2.34M
Total Liabilities Q2 2025 · Sep 30, 2024 $2.99M
Total Liabilities Q2 2025 · Mar 31, 2024 $2.58M
Current Assets Q2 2025 · Sep 30, 2024 $4.25M
Current Assets Q2 2025 · Mar 31, 2024 $3.71M
Total Assets Q2 2025 · Sep 30, 2024 $10.37M
Total Assets Q2 2025 · Mar 31, 2024 $9.9M
Shares Diluted Q2 2025 · Sep 30, 2023 54.3M sh
Shares Diluted Q2 2025 · Sep 30, 2023 53.7M sh
Capex Q2 2025 · Sep 30, 2023 $55K
Operating Cash Flow Q2 2025 · Sep 30, 2023 −$3.09M
Stockholders Equity Q2 2025 · Sep 30, 2023 $14.1M
Stockholders Equity Q2 2025 · Jun 30, 2023 $13.2M
Stockholders Equity Q2 2025 · Mar 31, 2023 $14.91M
Eps Diluted Q2 2025 · Sep 30, 2023 −$0.05
Eps Diluted Q2 2025 · Sep 30, 2023 −$0.08
Eps Basic Q2 2025 · Sep 30, 2023 −$0.05
Eps Basic Q2 2025 · Sep 30, 2023 −$0.08
Sga Expense Q2 2025 · Sep 30, 2023 $1.4M
Sga Expense Q2 2025 · Sep 30, 2023 $3.04M
Rd Expense Q2 2025 · Sep 30, 2023 $1.27M
Rd Expense Q2 2025 · Sep 30, 2023 $2.02M
Net Income Q2 2025 · Sep 30, 2023 −$2.45M
Net Income Q2 2025 · Sep 30, 2023 −$4.53M
Operating Income Q2 2025 · Sep 30, 2023 −$2.49M
Operating Income Q2 2025 · Sep 30, 2023 −$4.63M
Gross Profit Q2 2025 · Sep 30, 2023 $174K
Gross Profit Q2 2025 · Sep 30, 2023 $429K
Cost Of Revenue Q2 2025 · Sep 30, 2023 $117K
Cost Of Revenue Q2 2025 · Sep 30, 2023 $417K
Revenue Q2 2025 · Sep 30, 2023 $291K
Revenue Q2 2025 · Sep 30, 2023 $846K